XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -152.37%-40.09M | -384.30%-26.42M | -53.96%23.71M | -308.41%-36.86M | -102.14%-530K | -76.42%76.56M | -81.42%9.29M | -24.46%51.5M | -115.01%-9.02M | -83.05%24.8M |
Net income from continuing operations | 48.61%-131.17M | 77.24%-49.48M | -59.44%-36.07M | -87.90%-14.75M | -318.90%-30.87M | -166.65%-255.25M | -531.96%-217.41M | -124.21%-22.62M | -106.83%-7.85M | -105.93%-7.37M |
Depreciation and amortization | 9.41%62.25M | 16.44%16.11M | 5.77%17.93M | -6.55%14.32M | 28.82%13.88M | 2.51%56.89M | 0.35%13.84M | 27.84%16.95M | 9.35%15.32M | -25.34%10.78M |
Deferred tax | 1.74%-27.63M | 10.85%-15.89M | -45.24%-5.63M | 42.52%-1.54M | -22.16%-4.58M | -265.22%-28.12M | -407.03%-17.83M | -183.13%-3.87M | -151.80%-2.67M | -368.82%-3.75M |
Other non cash items | 10.80%29.13M | 31.38%29.67M | -49.95%1.54M | -48.87%997K | -133.97%-3.07M | 351.59%26.29M | 4,058.75%22.58M | 173.20%3.08M | 4,742.86%1.95M | 80.55%-1.31M |
Change In working capital | -78.96%21.29M | -123.15%-8.42M | -21.73%44.09M | -118.25%-37.44M | -10.11%23.06M | 182.47%101.2M | 272.44%36.37M | 242.13%56.33M | 77.00%-17.16M | 103.79%25.66M |
-Change in receivables | -101.96%-811K | -78.62%-12.01M | -49.13%6.76M | 85.04%-4.13M | -86.25%8.58M | -27.17%41.28M | -119.52%-6.73M | -43.09%13.29M | -27,188.24%-27.63M | 5,206.47%62.35M |
-Change in inventory | -36.15%68.83M | -51.41%18.73M | -41.97%29.32M | -112.75%-4.54M | 249.90%25.33M | 170.19%107.8M | 644.48%38.54M | 220.92%50.53M | 144.26%35.63M | 30.22%-16.9M |
-Change in prepaid assets | 171.66%9.11M | 488.16%6.3M | 148.87%2.09M | 57.47%-3.6M | -65.74%4.31M | 465.26%3.35M | -47.86%-1.62M | -94.65%841K | 3.15%-8.46M | 337.60%12.59M |
-Change in payables and accrued expense | 14.34%-42.2M | -195.80%-7.8M | 178.52%4.89M | -28.38%-24.14M | 53.21%-15.15M | -594.28%-49.27M | 129.01%8.14M | 83.15%-6.22M | -229.21%-18.8M | -174.75%-32.38M |
-Change in other working capital | -594.40%-13.63M | ---- | ---- | ---- | ---- | 89.83%-1.96M | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -152.37%-40.09M | -384.30%-26.42M | -53.96%23.71M | -308.41%-36.86M | -102.14%-530K | -76.42%76.56M | -81.42%9.29M | -24.46%51.5M | -115.01%-9.02M | -83.05%24.8M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 36.44%-34.21M | -122.35%-12.79M | 52.81%-4.01M | 52.06%-6.9M | 58.27%-10.51M | 25.22%-53.82M | 78.57%-5.75M | 46.63%-8.49M | -15.84%-14.4M | -50.04%-25.18M |
Capital expenditure reported | 36.51%-34.31M | -122.35%-12.79M | 52.61%-4.03M | 51.93%-6.98M | 58.41%-10.51M | 25.12%-54.04M | 78.60%-5.75M | 46.66%-8.5M | -16.21%-14.52M | -49.93%-25.27M |
Net PPE purchase and sale | -54.55%100K | --0 | 233.33%20K | -36.89%77K | -96.74%3K | 12.82%220K | --0 | -72.73%6K | 84.85%122K | 26.03%92K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 36.44%-34.21M | -122.35%-12.79M | 52.81%-4.01M | 52.06%-6.9M | 58.27%-10.51M | 25.22%-53.82M | 78.57%-5.75M | 46.63%-8.49M | -15.84%-14.4M | -50.04%-25.18M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 732.14%155.72M | 92,872.62%155.86M | 98.74%-23K | -100.10%-19K | -112.14%-98K | 110.62%18.71M | -460.00%-168K | -169.19%-1.82M | 126.40%19.89M | 100.78%807K |
Net issuance payments of debt | 3,638.63%174.78M | 117,441.61%174.84M | -130.00%-23K | -100.39%-19K | ---16K | 104.25%4.68M | -20.16%-149K | ---10K | 112.09%4.83M | --0 |
Net common stock issuance | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Cash dividends paid | --0 | --0 | --0 | --0 | --0 | 50.30%-5.13M | --0 | --0 | 0.12%-2.57M | 2.25%-2.57M |
Proceeds from stock option exercised by employees | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net other financing activities | -199.43%-19.06M | -99,800.00%-18.98M | --0 | --0 | -102.43%-82K | 384.02%19.17M | -100.71%-19K | -134.82%-1.81M | 734.52%17.63M | 401.97%3.37M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 732.14%155.72M | 92,872.62%155.86M | 98.74%-23K | -100.10%-19K | -112.14%-98K | 110.62%18.71M | -460.00%-168K | -169.19%-1.82M | 126.40%19.89M | 100.78%807K |
Net cash flow | ||||||||||
Beginning cash position | 31.37%176.88M | -18.17%141.41M | -8.65%120.73M | 21.97%165.19M | 31.37%176.88M | 134.10%134.64M | 57.97%172.81M | 136.70%132.16M | 59.24%135.44M | 134.10%134.64M |
Current changes in cash | 96.40%81.42M | 3,360.37%116.65M | -52.22%19.68M | -1,141.17%-43.78M | -2,714.08%-11.14M | -45.73%41.45M | -85.43%3.37M | -24.96%41.18M | 87.25%-3.53M | -98.36%426K |
Effect of exchange rate changes | -361.30%-2.05M | -358.14%-1.81M | 286.41%1M | -378.54%-688K | -247.99%-552K | 6.39%783K | -66.73%700K | 59.47%-537K | 115.78%247K | -75.49%373K |
End cash Position | 44.87%256.25M | 44.87%256.25M | -18.17%141.41M | -8.65%120.73M | 21.97%165.19M | 31.37%176.88M | 31.37%176.88M | 57.97%172.81M | 136.70%132.16M | 59.24%135.44M |
Free cash flow | -430.37%-74.4M | -1,207.91%-39.21M | -54.22%19.68M | -86.19%-43.83M | -2,234.25%-11.04M | -91.08%22.52M | -84.71%3.54M | -17.68%43M | -149.43%-23.54M | -100.37%-473K |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |